351456-45-6

Basic information

• Product Name: 5-CHLORO-3-IODO-1H-INDAZOLE
• Synonyms: 5-CHLORO-3-IODO-1H-INDAZOLE;5-CHLORO-3-IODOINDAZOLE;1H-Indazole, 5-chloro-3-iodo-;351456-46-5
• CAS NO: 351456-45-6
• Molecular Formula: C₇H₄ClIN₂
• Molecular Weight: 278.48
• Mol File: 351456-45-6.mol

Chemical Properties

• Boiling Point: 391.471 °C at 760 mmHg
• Flash Point: 190.555 °C
• Appearance: /
• Density: 2.157 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.785
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 5-CHLORO-3-IODO-1H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-3-IODO-1H-INDAZOLE(351456-45-6)
• EPA Substance Registry System: 5-CHLORO-3-IODO-1H-INDAZOLE(351456-45-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 351456-45-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-CHLORO-3-IODO-1H-INDAZOLE is used as a chemical intermediate for the synthesis of pharmaceutical compounds. Its unique structure and properties allow for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 5-CHLORO-3-IODO-1H-INDAZOLE is used as a building block for the synthesis of agrochemicals, such as pesticides and herbicides. Its unique structure can contribute to the development of more effective and environmentally friendly products.
Used in Materials Science:
5-CHLORO-3-IODO-1H-INDAZOLE is used in materials science for the development of new materials with specific properties. Its unique structure can be utilized to create materials with improved performance in various applications, such as electronics, coatings, and adhesives.
Used in Organic Synthesis:
As a chemical compound with chlorine and iodine substituents, 5-CHLORO-3-IODO-1H-INDAZOLE is used in various organic synthesis processes. Its reactivity and unique structure make it a valuable component in the synthesis of novel compounds with potential applications in different industries.
Used in Research and Development:
5-CHLORO-3-IODO-1H-INDAZOLE is used in research and development for the exploration of its potential applications and properties. Its unique structure and properties make it an interesting subject for scientific studies, which can lead to the discovery of new applications and uses in various fields.

InChI:InChI=1/C7H4ClIN2/c8-4-1-2-6-5(3-4)7(9)11-10-6/h1-3H,(H,10,11)

Upstream product

• 77-92-9 citric acid 
• 698-26-0 5-chloro-1H-indazole 

Downstream Products

• 13097-03-5 5-Chloro-3-phenylindazole 

Relevant articles and documents

SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF

Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particu

Suzuki-type cross-coupling reaction of unprotected 3-iodoindazoles with pinacol vinyl boronate: An expeditive C-3 vinylation of indazoles under microwave irradiation

Herein we report an expeditive C-3 vinylation of unprotected 3-iodoindazoles under microwave irradiation. Ten C-5 substituted 3-vinylindazole derivatives, nine of them novel, were synthesized through this method, which proceeds in moderate to excellent yields starting from C-5 substituted 3-iodoindazole derivatives. In all cases, the C-3 vinylated derivative was the only isolated product. This methodology allows access to 3-vinylated indazoles selectively and directly without the need of N-protection. 3-Vinylindazoles could be interesting synthetic intermediates allowing access to biologically active molecules.

THERAPEUTIC INHIBITORY COMPOUNDS

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds which are complement factor D inhibitors. Such compounds are useful for treating complement related disorders including, but are not limited to, autoimmune, inflammatory, and neurodegenerative diseases.

THERAPEUTIC INHIBITORY COMPOUNDS

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds which are complement factor D inhibitors. Such compounds are useful for treating complement related disorders including, but are not limited to, autoimmune, inflammatory, and neurodegenerative diseases.

New CRTh2 antagonists.

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

NEW CRTh2 ANTAGONISTS

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome

Using a structure based design approach we have identified a series of indazole substituted pyrrolopyrazines, which are potent inhibitors of JAK3. Intramolecular electronic repulsion was used as a strategy to induce a strong conformational bias within the ligand. Compounds bearing this conformation participated in a favorable hydrophobic interaction with a cysteine residue in the JAK3 binding pocket, which imparted high selectivity versus the kinome and improved selectivity within the JAK family.

Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation

Indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.